The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
Open accessAbstract
BACKGROUND: The use of n-3 fatty acids may prevent cardiovascular events in patients with recent myocardial infarction or heart failure. Their effects in patients with (or at risk for) type 2 diabetes mellitus are unknown. METHODS: In this double-blind study with a 2-by-2 factorial design, we randomly assigned 12,536 patients who were at high risk for cardiovascular events and had impaired fasting glucose, impaired glucose tolerance, or diabetes to receive a 1-g capsule containing at least 900 mg (90% or more) of ethyl esters of n-3 fatty acids or placebo daily and to receive either insulin glargine or standard care. The primary outcome was death from cardiovascular causes. The results of the comparison between n-3 fatty acids and placebo are reported here. RESULTS: During a median follow up of 6.2 years, the incidence of the primary outcome was not significantly decreased among patients receiving n-3 fatty acids, as compared with those receiving placebo (574 patients [9.1%] vs. 581 patients [9.3%]; hazard ratio, 0.98; 95% confidence interval [CI], 0.87 to 1.10; P=0.72). The use of n-3 fatty acids also had no significant effect on the rates of major vascular events (1034 patients [16.5%] vs. 1017 patients [16.3%]; hazard ratio, 1.01; 95% CI, 0.93 to 1.10; P=0.81), death from any cause (951 [15.1%] vs. 964 [15.4%]; hazard ratio, 0.98; 95% CI, 0.89 to 1.07; P=0.63), or death from arrhythmia (288 [4.6%] vs. 259 [4.1%]; hazard ratio, 1.10; 95% CI, 0.93 to 1.30; P=0.26). Triglyceride levels were reduced by 14.5 mg per deciliter (0.16 mmol per liter) more among patients receiving n-3 fatty acids than among those receiving placebo (P<0.001), without a significant effect on other lipids. Adverse effects were similar in the two groups. CONCLUSIONS: Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events. (Funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Even among omega‐3 fatty acid studies, there are marked differences with respect to the relatively low doses of omega‐3 administered and the ratio of EPA to DHA.16, 17, 18, 19, 20, 21, 22, 23, 24”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the ORIGIN trial, which enrolled more than 12,000 patients with impaired fasting glucose and at high risk for cardiovascular events, the administration of 1 g/day of combined EPA + DHA (465 mg of EPA and 375 mg of DHA) had no impact on cardiovascular mortality [89].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [89]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, many previous 20 , 21 , 22 , 23 and recently completed clinical studies 24 , 25 showed that ω3 PUFA supplementation did not offer significant favorable impacts on cardiovascular events.”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“The STRENGTH, VITAL, ASCEND, ORIGIN, OMEGA, ALPHA-OMEGA, GISSI-HF and GISSI-P trials randomized patients to receive either a combination of EPA and DHA or placebo; yet only the GISSI trials noted a statistically significant effect on cardiovascular events and mortality [96–103].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [99]
The cited source says what the claim attributes to it.
In the citing paper
“but subsequent larger trials failed to replicate these findings. 8,9”
From Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (2020) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Nevertheless, the dosage used in OMEMI was about twice that used in comparable earlier trials 5, 7, 23, 30 , although considerably lower than the dosage used in REDUCE-IT 14 , and also in the STRENGTH trial 36 .”
From Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction (2021) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“A limitation to the study is the inclusion rate of 26 % of screened candidates, which is relatively low compared to other n-3 PUFA trials not targeting elderly patients 30-33 .”
From Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction (2021) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“Other more recent omega‐3 therapy outcome studies conducted in the presence of statins have been less encouraging, but these studies were characterized by evaluating nonhypertriglyceridemic patient populations (eg, TG <200 mg/dL) and administering low doses of long‐chain omega‐3 fatty acids (eg, eicosapentaenoic acid [EPA] and/or docosoahexaenoic acid [DHA]).19, 20, 21, 22, 23, 24”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“Our initial manuscript included Trials such as ORIGIN8, ASCEND9, Alpha Omega10, and JELIS5; among these trials, only one trial had IPE, and the rest of the trials had a combination of EPA and DHA, so our results were skewed as search strategy missed significant studies.”
From Cardiovascular outcomes and coronary artery disease prevention secondary to icosapent ethyl: a meta-analysis of randomized clinical trials (2024) · cites this paper as [8]
In the citing paper
“Data from studies on supplementation with n-3 fatty acids do not support recommending n-3 fatty acid supplements for secondary prevention of CVD in T2DM.86,87”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [86]
In the citing paper
“In the ORIGIN (Outcome Reduction With Initial Glargine Intervention) trial, 12 537 patients (mean age 63.5 years) at high CVD risk with impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or T2DM were randomized to insulin glargine titrated to a fasting blood glucose level of ≤5.3 mmol/L (≤95 mg/dL) or standard care.86 After a median follow-up of 6.2 years, the incidence of CV”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [86]
In the citing paper
“The JELIS study692) conducted in Japan found that the addition of EPA to statins showed a significant preventive effect on major cardiovascular events compared to statin monotherapy.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [692]
In the citing paper
“Evidence does not conclusively support recommending n-3 (eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) supplements for all people with diabetes for the prevention or treatment of cardiovascular events (70,209,210).”
From 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes:Standards of Care in Diabetes—2023 (2023) · cites this paper as [210]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Lichtenstein, A. H., Appel, L. J., Brands, M., Carnethon, M., Daniels, S., Franch, H. A., Franklin, B., Kris-Etherton, P., Harris, W. S., Howard, B., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.176158 · Cited by 2,705
(1999) · PubMed · Cited by 2,062
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Self-citationGISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61239-8 · Cited by 1,350
Fish and Omega-3 Fatty Acid Intake and Risk of Coronary Heart Disease in Women
Hu, F. B. (2002) · JAMA · doi:10.1001/jama.287.14.1815 · Cited by 1,018
n–3 Fatty Acids and Cardiovascular Events after Myocardial Infarction
Kromhout, D., Giltay, E. J., & Geleijnse, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003603 · Cited by 936
n–3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored
Calder, P. C. (2004) · Clinical Science · doi:10.1042/cs20040119 · Cited by 571
Cardiovascular effects of marine omega-3 fatty acids
Saravanan, P., Davidson, N. C., Schmidt, E. B., & Calder, P. C. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60445-x · Cited by 513
Flagged first, then by citations
Research works printed but not linked: 1
- Gerstein H, 2008, Am Heart J, 155, 26
Cited by
Sorted by citations
Items 101–200 of 933
Boosting Inflammation Resolution in Atherosclerosis
Fredman, G., & Tabas, I. A. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.01.018 · Cited by 179
Oxidation of Marine Omega-3 Supplements and Human Health
Albert, B. B., Cameron‐Smith, D., Hofman, P. L., & Cutfield, W. S. (2013) · BioMed Research International · doi:10.1155/2013/464921 · Cited by 177
Borow, K. M., Nelson, J. R., & Mason, R. P. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.07.035 · Cited by 175
Balling, M., Afzal, S., Varbo, A., Langsted, A., Davey Smith, G., & Nordestgaard, B. G. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.09.610 · Cited by 175
Residual macrovascular risk in 2013: what have we learned?
(R3i), F. T. R. R. R. I., Fruchart, J., Davignon, J., Hermans, M. P., Al-Rubeaan, K. A., Amarenco, P., Assmann, G., Barter, P. J., Betteridge, J. D., Bruckert, É., et al. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-26 · Cited by 174
Omega-3 Index and Cardiovascular Health
von Schacky, C. (2014) · Nutrients · doi:10.3390/nu6020799 · Cited by 166
Hypertension with diabetes mellitus complications
Yamazaki, D., Hitomi, H., & Nishiyama, A. (2018) · Hypertension Research · doi:10.1038/s41440-017-0008-y · Cited by 166
Results of a reevaluation of cardiovascular outcomes in the RECORD trial
Mahaffey, K. W., Hafley, G. E., Dickerson, S., Burns, S., Tourt-Uhlig, S., White, J. A., Newby, L. K., Michel Komajda, N., McMurray, J. J. V., Bigelow, R., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.05.004 · Cited by 165
Mahendran, Y., Cederberg, H., Vangipurapu, J., Kangas, A. J., Soininen, P., Kuusisto, J., Uusitupa, M. I. J., Ala‐Korpela, M., & Laakso, M. (2013) · Diabetes Care · doi:10.2337/dc13-0800 · Cited by 164
Simonetto, M., Infante, M., Sacco, R. L., Rundek, T., & Della‐Morte, D. (2019) · Nutrients · doi:10.3390/nu11102279 · Cited by 164
Nestel, P., Clifton, P., Colquhoun, D., Noakes, M., Mori, T. A., Sullivan, D., & Thomas, B. (2015) · Heart, Lung and Circulation · doi:10.1016/j.hlc.2015.03.020 · Cited by 160
Surprises from genetic analyses of lipid risk factors for atherosclerosis
Musunuru, K., & Kathiresan, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306398 · Cited by 159
3. Foundations of Care and Comprehensive Medical Evaluation
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc16-s006 · Cited by 159
Effects of Fish n-3 PUFAs on Intestinal Microbiota and Immune System
Parolini, C. (2019) · Marine Drugs · doi:10.3390/md17060374 · Cited by 158
Dworatzek, P. D. N., Arcudi, K., Gougeon, R., Husein, N., Sievenpiper, J. L., & Williams, S. L. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.019 · Cited by 157
Mohan, D., Mente, A., Dehghan, M., Rangarajan, S., O'Donnell, M. J., Hu, W., Dagenais, G. R., Wielgosz, A. T., Lear, S. A., Li, W., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.0036 · Cited by 155
Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Abdelhamid, A. S., Martin, N., Bridges, C., Brainard, J. S., Wang, X., Brown, T. J., Hanson, S., Jimoh, F. O., Ajabnoor, S. M., Deane, K. H., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012345.pub3 · Cited by 151
Harris, W. S., Tintle, N., Etherton, M. R., & Vasan, R. S. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.02.010 · Cited by 149
Balfegó, M., Canivell, S., Hanzu, F. A., Sala‐Vila, A., Martínez-Medina, M., Murillo, S., Mur, T., Ruano, E. G., Linares, F., Porras, N., et al. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0245-0 · Cited by 147
Diet and Kidney Disease in High-Risk Individuals With Type 2 Diabetes Mellitus
Dunkler, D. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.9051 · Cited by 144
Elajami, T. K., Colas, R. A., Dalli, J., Chiang, N., Serhan, C. N., & Welty, F. K. (2016) · The FASEB Journal · doi:10.1096/fj.201500155r · Cited by 143
Puri, R., Nissen, S. E., Shao, M., Elshazly, M. B., Kataoka, Y., Kapadia, S. R., Tuzcu, E. M., & Nicholls, S. J. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.307601 · Cited by 143
Endothelial Dysfunction in Diabetes: Pathogenesis, Significance, and Treatment
Hamilton, S. J., & Watts, G. F. (2013) · The Review of Diabetic Studies · doi:10.1900/rds.2013.10.133 · Cited by 142
Omega-3 Polyunsaturated Fatty Acids: The Way Forward in Times of Mixed Evidence
Weylandt, K. H., Serini, S., Chen, Y. Q., Su, H., Lim, K., Cittadini, A. R. M., & Calviello, G. (2015) · BioMed Research International · doi:10.1155/2015/143109 · Cited by 142
Long-chain omega-3 fatty acids: time to establish a dietary reference intake
Flock, M. R., Harris, W. S., & Kris‐Etherton, P. M. (2013) · Nutrition Reviews · doi:10.1111/nure.12071 · Cited by 141
Chilton, F. H., Dutta, R., Reynolds, L. M., Sergeant, S., Mathias, R. A., & Seeds, M. C. (2017) · Nutrients · doi:10.3390/nu9111165 · Cited by 140
Ye, X., Kong, W., Zafar, M. I., & Chen, L.-L. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0851-z · Cited by 138
Risk Prediction for Early CKD in Type 2 Diabetes
Dunkler, D., Gao, P., Lee, S. F., Heinze, G., Clase, C. M., Tobe, S. W., Teo, K. K., Gerstein, H. C., Mann, J. F. E., & Oberbauer, R. W. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10321014 · Cited by 136
Watanabe, Y., & Tatsuno, I. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.50658 · Cited by 135
Effect of Dietary Fatty Acids on Human Lipoprotein Metabolism: A Comprehensive Update
Ooi, E. M. M., Watts, G. F., Ng, T., & Barrett, P. H. R. (2015) · Nutrients · doi:10.3390/nu7064416 · Cited by 130
Ninomiya, T., Nagata, M., Hata, J., Hirakawa, Y., Ozawa, M., Yoshida, D., Ohara, T., Kishimoto, H., Mukai, N., Fukuhara, M., et al. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.09.023 · Cited by 130
Weichselbaum, E., Coe, S., Buttriss, J. L., & Stanner, S. A. (2013) · Nutrition Bulletin · doi:10.1111/nbu.12021 · Cited by 129
Management of diabetic dyslipidemia: An update
Jialal, I., & Singh, G. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i5.280 · Cited by 128
Sala-Vila, A., Díaz-López, A., Valls-Pedret, C., Cofán, M., García-Layana, A., Lamuela-Raventós, R.-M., Castañer, O., Zanon-Moreno, V., Martinez-Gonzalez, M. A., Toledo, E., et al. (2016) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2016.2906 · Cited by 124
Capurso, C. A., Bellanti, F., Buglio, A. L., & Vendemiale, G. (2019) · Nutrients · doi:10.3390/nu12010035 · Cited by 124
Fleming, J. A., & Kris‐Etherton, P. M. (2014) · Advances in Nutrition · doi:10.3945/an.114.005850 · Cited by 123
AbuMweis, S., Jew, S., Tayyem, R., & Agraib, L. (2018) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.12493 · Cited by 122
Bonds, D. E., Harrington, M., Worrall, B. B., Bertoni, A. G., Eaton, C. B., Hsia, J., Robinson, J., Clemons, T. E., Fine, L. J., & Chew, E. Y. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.328 · Cited by 118
Demystifying the management of hypertriglyceridaemia
Watts, G. F., Ooi, E. M. M., & Chan, D. C. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.140 · Cited by 115
Health Benefits, Food Applications, and Sustainability of Microalgae-Derived N-3 PUFA
Liu, Y., Ren, X., Fan, C., Wu, W., Zhang, W., & Wang, Y. (2022) · Foods · doi:10.3390/foods11131883 · Cited by 115
Effect of omega-3 supplementation on neuropathy in type 1 diabetes
Lewis, E. J. H., Perkins, B. A., Lovblom, L. E., Bazinet, R. P., Wolever, T. M. S., & Bril, V. (2017) · Neurology · doi:10.1212/wnl.0000000000004033 · Cited by 113
Marine OMEGA-3 fatty acids in the prevention of cardiovascular disease
Mori, T. A. (2017) · Fitoterapia · doi:10.1016/j.fitote.2017.09.015 · Cited by 111
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
Is Grassfed Meat and Dairy Better for Human and Environmental Health?
Provenza, F. D., Kronberg, S. L., & Gregorini, P. (2019) · Frontiers in Nutrition · doi:10.3389/fnut.2019.00026 · Cited by 109
Chinese Guideline on the Primary Prevention of Cardiovascular Diseases
Chinese Society of Cardiology of Chinese Medical Association, C. D. P. A. R. C. O. C. A. O. R. M. (2021) · Cardiology Discovery · doi:10.1097/cd9.0000000000000025 · Cited by 109
Overview of omega-3 Fatty Acid therapies.
Bradberry, J. C., & Hilleman, D. E. (2013) · PubMed Central · Cited by 109
Mason, R. P., & Sherratt, S. C. R. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.12.127 · Cited by 108
Maki, K. C., Palacios, O. M., Bell, M., & Toth, P. P. (2017) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2017.07.010 · Cited by 107
Pros and Cons of Long-Chain Omega-3 Polyunsaturated Fatty Acids in Cardiovascular Health
Djuricic, I. D., & Calder, P. C. (2023) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-051921-090208 · Cited by 107
Albert, B. B., Derraik, J. G. B., Brennan, C. M., Biggs, J. B., Smith, G. C., Garg, M. L., Cameron-Smith, D., Hofman, P. L., & Cutfield, W. S. (2014) · Scientific Reports · doi:10.1038/srep06697 · Cited by 105
Chamberlain, J. J., Johnson, E. L., Leal, S., Rhinehart, A. S., Shubrook, J. H., & Peterson, L. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0222 · Cited by 105
Clinical Advances in Immunonutrition and Atherosclerosis: A Review
Ruiz-León, A. M., Lapuente, M., Estruch, R., & Casas, R. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00837 · Cited by 104
Inflammation and cardiovascular disease: are marine phospholipids the answer?
Lordan, R., Redfern, S., Τσούπρας, Α., & Zabetakis, I. (2020) · Food & Function · doi:10.1039/c9fo01742a · Cited by 104
Orringer, C. E., Jacobson, T. A., & Maki, K. C. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.10.014 · Cited by 103
Franz, M. J., Boucher, J. L., & Evert, A. B. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s45140 · Cited by 103
Africa, J. A., Newton, K. P., & Schwimmer, J. B. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4126-1 · Cited by 102
Baseline characteristics of participants in the VITamin D and OmegA-3 TriaL (VITAL)
Bassuk, S. S., Manson, J. E., Lee, I.-M. M., Cook, N. R., Christen, W. G., Bubes, V. Y., Gordon, D., Copeland, T., Friedenberg, G., D’Agostino, D., et al. (2016) · Contemporary Clinical Trials · doi:10.1016/j.cct.2015.12.022 · Cited by 101
Omega-3 fatty Acids in cardiovascular disease – An uphill battle
von Schacky, C. (2014) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2014.05.004 · Cited by 100
Poręba, M., Mostowik, M., Siniarski, A., Gołębiowska-Wiatrak, R., Malinowski, K. P., Haberka, M., Konduracka, E., Nessler, J., Undas, A., & Gajos, G. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0523-9 · Cited by 100
Omega-3 Fatty Acid Blood Levels
Superko, H. R., Superko, S. M., Nasir, K., Agatston, A. A., & Garrett, B. C. (2013) · Circulation · doi:10.1161/circulationaha.113.002731 · Cited by 100
Wen, Y. T., Dai, J. H., & Gao, Q. (2014) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2013.12.004 · Cited by 98
Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction
Kim, N. H., & Kim, S. G. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0001 · Cited by 98
An Improvement of Cardiovascular Risk Factors by Omega-3 Polyunsaturated Fatty Acids
Yanai, H., Masui, Y., Katsuyama, H., Adachi, H., Kawaguchi, A., Hakoshima, M., Waragai, Y., Harigae, T., & Sako, A. (2018) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3362w · Cited by 98
Yamagata, K. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0514-6 · Cited by 97
Role of EPA in Inflammation: Mechanisms, Effects, and Clinical Relevance
Crupi, R., & Cuzzocrea, S. (2022) · Biomolecules · doi:10.3390/biom12020242 · Cited by 97
Omega-3 polyunsaturated fatty acids for cardiovascular diseases: present, past and future
Watanabe, Y., & Tatsuno, I. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1333902 · Cited by 95
Wolfram, G., Bechthold, A., Boeing, H., Ellinger, S., Hauner, H., Kroke, A., Leschik-Bonnet, E., Linseisen, J., Lorkowski, S., Schulze, M., et al. (2015) · Annals of Nutrition and Metabolism · doi:10.1159/000437243 · Cited by 94
ω-3 Fatty Acids and Cardiovascular Diseases: Effects, Mechanisms and Dietary Relevance
Mæhre, H. K., Jensen, I., Elvevoll, E. O., & Eilertsen, K. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160922636 · Cited by 93
Nitro-fatty acids: New drug candidates for chronic inflammatory and fibrotic diseases
Schopfer, F. J., Vitturi, D. A., Jorkasky, D. K., & Freeman, B. Α. (2018) · Nitric Oxide · doi:10.1016/j.niox.2018.06.006 · Cited by 93
Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Health: A Comprehensive Review
Elagizi, A., Lavie, C. J., Marshall, K., DiNicolantonio, J. J., O’Keefe, J. H., & Milani, R. V. (2018) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.03.006 · Cited by 92
Nutraceuticals as therapeutic agents for atherosclerosis
Moss, J. W. E., Williams, J. O., & Ramji, D. P. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.02.006 · Cited by 89
The Effects of Fish Oil on Cardiovascular Diseases: Systematical Evaluation and Recent Advance
Liao, J., Xiong, Q., Yin, Y., Ling, Z., & Chen, S. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.802306 · Cited by 89
Nutritional Strategies for the Management of Type 2 Diabetes Mellitus: A Narrative Review
Minari, T. P., Tácito, L. H. B., Yugar, L. B. T., Ferreira‐Melo, S. E., Manzano, C. F., Pires, A. C., Moreno, H., Vilela-Martin, J. F., Cosenso‐Martin, L. N., & Yugar‐Toledo, J. C. (2023) · Nutrients · doi:10.3390/nu15245096 · Cited by 91
Mason, R. P., Dawoud, H., Jacob, R. F., Sherratt, S. C. R., & Maliñski, T. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.118 · Cited by 87
New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
Kim, K., Ginsberg, H. N., & Choi, S. H. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0198 · Cited by 88
Bordeleau, L. J., Yakubovich, N., Dagenais, G. R., Rosenstock, J., Probstfield, J. L., Yu, P. C., Rydén, L., Pīrāgs, V., Spinas, G. A., Birkeland, K. I., et al. (2014) · Diabetes Care · doi:10.2337/dc13-1468 · Cited by 86
The Treatment of Disorders of Lipid Metabolism
Parhofer, K. G. (2016) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2016.0261 · Cited by 86
Hosseini, B., Nourmohammadi, M., Hajipour, S., Taghizadeh, M., Asemi, Z., Keshavarz, S. A., & Jafarnejad, S. (2018) · Journal of Dietary Supplements · doi:10.1080/19390211.2018.1431753 · Cited by 86
Progressing Insights into the Role of Dietary Fats in the Prevention of Cardiovascular Disease
Zock, P. L., Blom, W. A. M., Nettleton, J. A., & Hornstra, G. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0793-y · Cited by 85
“Fishing” for the Origins of the “Eskimos and Heart Disease” Story: Facts or Wishful Thinking?
FODOR, J. G., Helis, E., Yazdekhasti, N., & Vohnout, B. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.04.007 · Cited by 84
the DPS Study Group, Takkunen, M. J., Schwab, U., de Mello, V. D., Eriksson, J. G., Lindström, J., Tuomilehto, J. O., & Uusitupa, M. I. J. (2015) · European Journal of Nutrition · doi:10.1007/s00394-015-0911-4 · Cited by 83
Dry Eye Assessment and Management (DREAM©) Study: Study design and baseline characteristics
Asbell, P. A., Maguire, M. G., Peskin, E., Bunya, V. Y., & Kuklinski, E. J. (2018) · Contemporary Clinical Trials · doi:10.1016/j.cct.2018.06.002 · Cited by 82
WEINTRAUB, H. S. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.07.041 · Cited by 82
Pro-resolving lipid mediators in vascular disease
Conte, M. S., Desai, T. A., Wu, B., Schaller, M. S., & Werlin, E. C. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97947 · Cited by 82
Fish, Fish Oils and Cardioprotection: Promise or Fish Tale?
Goel, A., Pothineni, N. V. K., Singhal, M., Paydak, H., Saldeen, T. G. P., & Mehta, J. L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123703 · Cited by 82
Omega-3 Fatty Acids and Cardiovascular Disease: New Developments and Applications
Harris, W. S., Dayspring, T. D., & Moran, T. J. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.11.2717 · Cited by 81
Mori, T. A. (2014) · Food & Function · doi:10.1039/c4fo00393d · Cited by 81
Saroglitazar for the treatment of dyslipidemia in diabetic patients
Joshi, S. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1009894 · Cited by 81
Fialkow, J. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0170-7 · Cited by 80
Sievenpiper, J. L., & Dworatzek, P. D. N. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2012.11.001 · Cited by 80
Shoji, T., Kakiya, R., Hayashi, T., Tsujimoto, Y., Sonoda, M., Shima, H., Mori, K., Fukumoto, S., Tahara, H., Shioi, A., et al. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.02.362 · Cited by 79
Bae, J. H., Lim, H., & Lim, S. (2023) · Advances in Nutrition · doi:10.1016/j.advnut.2023.03.014 · Cited by 78
Update on the Vitamin D and OmegA-3 trial (VITAL)
Pradhan, A. D., & Manson, J. E. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.04.006 · Cited by 77
Dietary n-3 PUFA and CVD: a review of the evidence
Mori, T. A. (2013) · Proceedings of The Nutrition Society · doi:10.1017/s0029665113003583 · Cited by 77
Nissen, S. E., Lincoff, A. M., Wolski, K., Ballantyne, C. M., Kastelein, J. J. P., Ridker, P. M., Ray, K. K., McGuire, D. K., Mozaffarian, D., Koenig, W., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.1157 · Cited by 76
Vitamin D, Marine n-3 Fatty Acids, and Primary Prevention of Cardiovascular Disease Current Evidence
Manson, J. E., Bassuk, S. S., Cook, N. R., Lee, I.-M. M., Mora, S., Albert, C. M., & Buring, J. E. (2020) · Circulation Research · doi:10.1161/circresaha.119.314541 · Cited by 76
Posicionamento sobre o Consumo de Gorduras e Saúde Cardiovascular – 2021
Izar, M. C. D. O., Lottenberg, A. M., Giraldez, V. Z. R., Santos, R. D., Machado, R. M., Bertolami, A., Assad, M. H. V., Saraiva, J. F. K., Faludi, A. Á., Moreira, A. S. B., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20201340 · Cited by 78
Fit with good fat? The role of n-3 polyunsaturated fatty acids on exercise performance
Boit, M. D., Hunter, A. M., & Gray, S. R. (2016) · Metabolism · doi:10.1016/j.metabol.2016.10.007 · Cited by 76
O’Connell, T. D., Block, R., Huang, S., & Shearer, G. C. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2016.12.003 · Cited by 76
Cardiovascular Disease in Diabetes Mellitus
Szuszkiewicz-Garcia, M., & Davidson, J. A. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.09.001 · Cited by 76
Metadata
- Authors
- The ORIGIN Trial Investigators
- Corresponding author
- The ORIGIN Trial Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-07-26
- Volume
- 367
- Issue
- 4
- Pages
- 309-318
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1560062315
- Semantic Scholar
- 00cc8344ced92b3c8921b97df8607e6b3032e111
- Cited by
- 929
- References
- 21
- Citations by year
- 2026: 19 · 2025: 23 · 2024: 41 · 2023: 53 · 2022: 51 · 2021: 57 · 2020: 76 · 2019: 60 · 2018: 72 · 2017: 56 · 2016: 90 · 2015: 79 · 2014: 90 · 2013: 122 · 2012: 38
- FWCI
- 97.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Monash University Research Portal (Monash University) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- IRIS (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- omega-3 fatty acids, cardiovascular outcomes, type 2 diabetes, dysglycemia, impaired fasting glucose, impaired glucose tolerance, insulin glargine, cardiovascular mortality, major vascular events, triglycerides, serum lipids, cardiac arrhythmias, cardiovascular risk reduction, dietary supplementation, omega-3 fatty acid ethyl esters
- MeSH terms
- Insulin Glargine, Aged, Cardiovascular Diseases, Cholesterol, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Male, Middle Aged, Triglycerides, Fatty Acids, Omega-3, Incidence, Proportional Hazards Models, Treatment Failure, Glucose Intolerance, Insulin, Long-Acting, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
